Renal Functional Contrast-Enhanced Magnetic Resonance Imaging

Mandry, Damien; Pedersen, Michael; Odille, Freddy; Robert, Philippe; Corot, Claire; Felblinger, Jacques; Grenier, N.; Claudon, M.

doi:10.1097/01.rli.0000160546.04884.91

Cited by 21 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to T 2 contrast agents, T 1 contrast agents can not only brighten the region of interest, but can also avert the partial-volume effects, which provide a higher signal-to-noise ratio and faster scanning. 6,20,21 Due to long electronic relaxation time and a large magnetic moment, Gd 3+ chelates are most commonly used for MRI T 1 contrast enhancement. 3 However, gadolinium-based clinical contrast agents suffer from their low relaxivity, poor pharmacokinetics, and potential release of detrimental metal ions by transmetalation in a physiological environment, which reduces the sensitivity of contrast agents and limits their applications in diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T₁contrast ability

Zhao

Zhang

et al. 2016

Nanoscale

View full text Add to dashboard Cite

High-performance magnetic resonance imaging (MRI) contrast agents and novel contrast enhancement strategies are urgently needed for sensitive and accurate diagnosis. Here we report a strategy to construct a new T1 contrast agent based on the Solomon-Bloembergen-Morgan (SBM) theory. We loaded the ultrasmall gadolinium oxide nanoparticles into worm-like interior channels of mesoporous silica nanospheres (Gd2O3@MSN nanocomposites). This unique structure endows the nanocomposites with geometrical confinement, high molecular tumbling time, and a large coordinated number of water molecules, which results in a significant enhancement of the T1 contrast with longitudinal proton relaxivity (r1) as high as 45.08 mM(-1) s(-1). Such a high r1 value of Gd2O3@MSN, compared to those of ultrasmall Gd2O3 nanoparticles and gadolinium-based clinical contrast agents, is mainly attributed to the strong geometrical confinement effect. This strategy provides new guidance for developing various high-performance T1 contrast agents for sensitive imaging and disease diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T₁contrast ability

Zhao

Zhang

et al. 2016

Nanoscale

View full text Add to dashboard Cite

show abstract

“…However, the quantitative assessment of renal perfusion is impaired by the rapid diffusion of the contrast agent into the extracellular space and thus, only iron oxide particles or blood pool Gd3 + chelates (macromolecular or albumin-bound) can be considered as blood pool contrast agents and thus reliably applied to the measurement of renal perfusion [4]. Recently, P792, a macromolecular Gd3 + -based blood pool agent, has been shown to improve renal functional MRI assessment in rats by inducing less T2* effect without compromising T1 enhancement [14]. …”

Section: Dynamic Serial Gadolinium-enhanced Mrimentioning

confidence: 99%

Magnetic Resonance Imaging in Acute and Chronic Kidney Diseases: Present Status

Laissy¹,

Idée

Fernandez³

et al. 2006

Nephron Clin Pract

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) of normal and diseased kidneys shows great promise because of the combined value of anatomical and functional information provided, as well as of specific contrast patterns that can be observed non-invasively. Multicontrast MRI is able to show infiltrative kidney disorders. Diffusion-weighted imaging can assess alterations in renal function and can suggest obstruction or inflammation when present. Due to the low nephrotoxicity, contrast-enhanced MR studies using serial dynamic enhancement with non-specific gadolinium chelates are able to provide information on glomerular filtration. Furthermore, contrast agents such as ultrasmall particles of iron oxide, specific of inflammation, should be used in the near future to detect active from quiescent involvement, both in native kidneys and renal allografts. Early results should indicate that these compounds might differentiate acute tubular necrosis from other acute nephropathies, as well as active proliferative nephropathies from chronic ones. Ongoing studies will obviously demonstrate the value of the combination of these various MRI sequences in the diagnosis of acute renal failure and chronic kidney disease.

show abstract

Contrast Agents: Magnetic Resonance

Burtéa

Laurent

Elst

et al. 2008

Molecular Imaging I

112

View full text Add to dashboard Cite

Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s(-1) mmol(-1) 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, gammaFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.

show abstract

Renal Functional Contrast-Enhanced Magnetic Resonance Imaging

Abstract: Due to its physicochemical and pharmacokinetic properties, P792 allows the use of a reduced dosage of gadolinium, resulting in less T2* effect without compromising T1 enhancement. Thus, P792 appears suitable for renal functional MR imaging.

Cited by 21 publications

References 41 publications

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T₁contrast ability

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T₁contrast ability

Magnetic Resonance Imaging in Acute and Chronic Kidney Diseases: Present Status

Contrast Agents: Magnetic Resonance

Contact Info

Product

Resources

About

Renal Functional Contrast-Enhanced Magnetic Resonance Imaging

Abstract: Due to its physicochemical and pharmacokinetic properties, P792 allows the use of a reduced dosage of gadolinium, resulting in less T2* effect without compromising T1 enhancement. Thus, P792 appears suitable for renal functional MR imaging.

Cited by 21 publications

References 41 publications

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T1contrast ability

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T1contrast ability

Magnetic Resonance Imaging in Acute and Chronic Kidney Diseases: Present Status

Contrast Agents: Magnetic Resonance

Contact Info

Product

Resources

About

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T₁contrast ability

Geometrically confined ultrasmall gadolinium oxide nanoparticles boost the T₁contrast ability